109 DIVISION OF HEM/ONC: ONCOLOGY BOARD REVIEW CONFERENCE " Bladder Cancer 2 + Fellow Cases " (041422)

Dallas, TX US
April 14, 2022
Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
04/14/2022
Course expires: 
04/14/2022
Event starts: 
04/14/2022 - 7:30am CDT
Event ends: 
04/14/2022 - 8:30am CDT
Cost:
$0.00
Part of: 
109 DIVISION OF HEM/ONC: ONCOLOGY BOARD REVIEW CONFERENCE 2022
Add to calendar: 
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390
United States
Speaker(s)

Tian Zhang, MD, MHS

has a financial relationship (Grant Or Contract) with Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeron, Mirati Therapeutics, Janssen, AstraZeneca, Pfizer, OmniSeq, Personal Genome Diagnostics, Astellas;.
has a financial relationship (Professional Services) with Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Pharmacyclics, SeaGen, Calithera, Dendreon, QED Therapeutics, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly;.
has a financial relationship (Professional Services) with Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options;.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.